Prostate cancer — all decisions

The Board denied service connection for prostate cancer, hemophilia, and diabetes mellitus (type 1 or type 2) as the evidence did not support a finding of an in-service incurrence or relationship to service.

The Board granted service connection for non-allergic rhinitis, lung nodules, prostate cancer, and diabetes mellitus due to herbicide agent exposure. The claims for an ocular disorder and kidney disease were denied.

The Veteran withdrew all appeals, including those for service connection and higher ratings for various conditions.

The Board denied the veteran's claims for an increased rating for residuals of prostate cancer and individual unemployability.

The Veteran withdrew his appeal for service connection for prostate cancer, and the Board has no jurisdiction to review this claim.

The Board granted the restoration of the 100 percent rating for prostate cancer, which was previously reduced to 20 percent effective October 1, 2024.

The Veteran withdrew all pending claims, and the Board has no jurisdiction to review these issues.

The Board granted service connection for the cause of the Veteran's death, finding that his prostate cancer was related to in-service asbestos exposure.

The Board granted service connection for prostate cancer, Parkinson's disease, type 2 diabetes mellitus, and erectile dysfunction (ED) as secondary to service-connected disabilities.

The Board remands the claim for service connection for prostate cancer to correct a pre-decisional duty to assist error, specifically to obtain an adequate medical opinion regarding the etiology of the Veteran's condition.

The Board remands the claim for service connection of residuals of prostate cancer to ensure that the case is forwarded to the Under Secretary for Benefits for consideration under 38 C.F.R. § 3.311.

The Board granted service connection for kidney cancer as secondary to the service-connected hypertension and granted a total rating based on individual employability due to service-connected disabilities from March 19, 2024. Other claims were denied.

The Board restored the 100 percent rating for prostate cancer effective April 1, 2024, as the procedural requirements were not met during the reduction process. The claim for an increased rating is rendered moot.

The Board granted service connection for a heart disability, to include coronary artery disease and valvular heart disease, and prostate cancer residuals under the PACT Act.

The Veteran's prostate cancer residuals are granted a 60 percent rating from July 7, 2023.

The Board denied the veteran's appeal for service connection claims due to untimely filings and lack of good cause.

The Board remands the claims for service connection for hypertension and prostate cancer status post prostatectomy as additional development is needed.

The Board remands the claim for service connection of prostate cancer to obtain a new medical opinion as the previous one was deemed inadequate.

The Board dismissed the Veteran's motion for revision based on clear and unmistakable error (CUE) in an April 2022 rating decision, as it was not properly raised with the AOJ first.

The Board remands the claims for service connection for various disabilities, including foot, ankle, knee, elbow, leg varicose veins, colon cancer, prostate disability, and psychiatric disability, to correct pre-decisional duty to assist omissions.